Retinopathy of prematurity.
Premature infants born at 30 weeks' gestational age or younger, or 1500 g or smaller, are screened for retinopathy of prematurity (ROP). Guidelines for supplemental oxygen in neonatal intensive care units have decreased but not eliminated the incidence of severe ROP. The underlying cause for ROP is prematurity and low birth weight, and with the survival of smaller and younger babies, ROP continues to be a significant problem facing premature infants. Threshold ROP is treated with retinal photocoagulation, but newer treatments such as intraocular injections of bevacizumab (Avastin) are being used alone or in conjunction with laser.
Department of Ophthalmology, Nationwide Children's Hospital, 555 South 18th Street, Suite 4C, Columbus, OH 43025, USA. Electronic address: cateolsonjordan@gmail.com.
Catherine O
CO
Jordan
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002648:Child; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D007223:Infant; D007230:Infant, Low Birth Weight; D007231:Infant, Newborn; D007234:Infant, Premature; D017075:Laser Coagulation; D012178:Retinopathy of Prematurity / Q000453:epidemiology / Q000628:therapy; D012307:Risk Factors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab
Low birth weight; Prematurity; Retinopathy of prematurity (ROP); Retrolental fibroplasia; Vascular endothelial growth factor inhibitors